Idrofos
Idrofos (Ibandronate 150 mg) — Sun Pharma monthly oral bisphosphonate for osteoporosis and bone metastases. Strict empty-stomach upright-30-min dosing rule.
✓ Medicinskt granskad av Morgan Ellis — Apoteksforskare · 8 års erfarenhet · Senast granskad: maj 2026
Quick Answer
Idrofos — Ibandronate 150 mg (Sun Pharma). Bisphosphonate — for cancer-related bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia, Paget’s disease, and severe osteoporosis. oral.
Vad du får med MedsBase:
- WHO-GMP-certifierad tillverkare
- Diskret förpackning i vanligt kuvert
- Världsvid leverans
- Betygsatt av 1 400+ kunder (läs recensioner)
📦 Reshipment Assurance: om din order inte har anlänt 20 arbetsdagar efter försändelse, skickar vi en ny utan extra kostnad. Läs policyn.
Varför beställa från MedsBase
Idrofos ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All bisphosphonates carry ONJ risk — higher with IV agents (zoledronic acid, ibandronate IV) and longer cumulative therapy. Pre-treatment dental review is mandatory; complete invasive dentistry before starting. Avoid invasive dental procedures during therapy if possible. Notify dentist about bisphosphonate use lifelong (effects persist years after stopping).
Bisphosphonates are renally cleared. Adequate hydration before/during IV administration. Monitor renal function and serum calcium. Hypocalcaemia is common; supplement with calcium + vitamin D throughout therapy. Avoid in CrCl <30 (oral) or <35 (IV).
Take first thing in the morning with a full glass (200 mL) of plain water — NO food, drink, or other medications. Remain upright (sitting or standing) for at least 30-60 minutes after the dose to prevent oesophagitis and oesophageal stricture. Then have breakfast and any other medications.
Vanliga frågor
When is this used?
Bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia (zoledronic acid IV is fastest), Paget’s disease, and severe osteoporosis (especially adjuvant during AI therapy in breast cancer).
IV vs oral?
IV (zoledronic acid 4 mg q3-4 weekly for cancer; q12 monthly for osteoporosis; ibandronate 6 mg q3-4 weekly): more potent, fewer doses, no GI absorption issues. Oral (ibandronate 150 mg monthly): convenient, no IV access needed, but oesophagitis risk and absorption issues.
ONJ — how worried should I be?
ONJ is rare but cumulative. Risk factors: invasive dental procedures (extraction, implants), poor dental hygiene, smoking, diabetes, glucocorticoid use. Pre-treatment dental review and ongoing oral hygiene minimise risk. Discuss any planned dental work with your oncology team.
Calcium and vitamin D?
Mandatory throughout bisphosphonate therapy: calcium 1000-1500 mg/day plus vitamin D 800-1000 IU/day. Reduces hypocalcaemia risk and improves bone density.
Läkemedelsinteraktioner?
Calcium, magnesium, aluminium-containing antacids, iron, multivitamins reduce absorption (oral) — separate by ≥30 minutes. NSAIDs + bisphosphonates: increased GI risk. Aminoglycosides + bisphosphonates: increased nephrotoxicity.
Graviditet?
Long half-life in bone (years to decades). Generally avoided in pre-menopausal women without effective contraception. Limited human pregnancy data.
Vad händer om jag missar en dos?
Oral monthly: take next morning if remembered the same week; if missed entirely, return to the original schedule next month. IV: scheduled by specialist; reschedule with oncology team.
Atypical femoral fracture?
Rare class effect after long-term use (typically >5 years osteoporosis use). Drug holiday at 3-5 years considered in osteoporosis. Cancer use typically continues based on disease state.
Acute phase reaction?
Common after first IV bisphosphonate dose: fever, myalgia, arthralgia, fatigue 1-3 days post-infusion. Usually mild, paracetamol-responsive, less severe with subsequent doses.
Stopping?
Specialist-determined based on disease, response, toxicity. Bisphosphonate effect on bone persists for years after stopping due to bone deposition.
Other Cancer & Bone-Health Medications
- Zoldria — zoledronic acid IV — for bone mets and hypercalcaemia
- Bandrone — ibandronate — alternative bisphosphonate
- Idrofos — ibandronate 150 mg monthly oral
- Osteofos — alendronate weekly — for osteoporosis
- Calcirol — vitamin D3 60,000 IU sachet — for adequacy
More options in Anti Cancer Medication
Rangerade efter senaste ordervolym på MedsBase — vad andra kunder i denna kategori väljer.
| Styrka | 150 mg |
|---|---|
| Kvantitet | 1 Tablet/s, 3 Tablet/s, 6 Tablet/s |
| Farmaceutisk form | Tabletter |
| Tillverkare | Sun Pharma |
| Behandling | Osteoporosis |
| Generiskt märke | Ibandronic Acid |
Idrofos
Frågor & svar
Idrofos
Relaterade produkter
Recensioner
Det finns inga recensioner än